Epiq Capital Group, LLC Cyclo Therapeutics, Inc. Transaction History
Epiq Capital Group, LLC
- $342 Million
- Q4 2024
A detailed history of Epiq Capital Group, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Epiq Capital Group, LLC holds 689,447 shares of CYTH stock, worth $634,291. This represents 0.11% of its overall portfolio holdings.
Number of Shares
689,447
Previous 739,426
6.76%
Holding current value
$634,291
Previous $584,000
32.88%
% of portfolio
0.11%
Previous 0.18%
Shares
4 transactions
Others Institutions Holding CYTH
# of Institutions
21Shares Held
2.24MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA599KShares$550,7980.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$442,25116.84% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$140,1450.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$101,221100.0% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$54,7490.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $7.76M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...